Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989056 | 1.00 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL3644211 | 0.79 | XDH (0.41) | ALDH1A1L3MBTL1PIN1KMT2AMEN1 | |
| SCHEMBL23029862 | 0.77 | CSNK1A1 (0.38) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL29464288 | 0.77 | KMT2A (0.46) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL2401423 | 0.77 | KMT2A (0.46) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL25695712 | 0.75 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL24533739 | 0.75 | NUDT1 (0.36) | ALDH1A1L3MBTL1PIN1KMT2ACSNK1A1 | |
| SCHEMBL2463467 | 0.75 | LMNA (0.39) | ALDH1A1L3MBTL1PIN1KMT2AMEN1 | |
| SCHEMBL20172034 | 0.75 | PIN1 (0.33) | ALDH1A1L3MBTL1PIN1KMT2AMEN1 | |
| SCHEMBL3646724 | 0.75 | LMNA (0.39) | ALDH1A1L3MBTL1PIN1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| CN-118359642-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024125603-A1 | SHP2 INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-118206550-A | SHP2 inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111566104-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-117143079-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-111138412-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-3712151-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3712151-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| CN-111592525-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111566104-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-111138412-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-110655520-A | Pyrimido-cyclic compounds, process for their preparation and their use | 上海青煜医药科技有限公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | PTPN1, PTPN11, PTPN5 | ALDH1A1 1964/4885L3MBTL1 4112/4885PIN1 139/4885 |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | PTPN1, PTPN11, PTPN5 | ALDH1A1 1964/4885L3MBTL1 4112/4885PIN1 139/4885 |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | ALDH1A1 1919/4885L3MBTL1 4306/4885PIN1 127/4885 |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | PTPN1, PTPN11, PTPN5 | ALDH1A1 1919/4885L3MBTL1 4306/4885PIN1 127/4885 |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | ALDH1A1 1919/4885L3MBTL1 4306/4885PIN1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.